Last updated: February 20, 2026
What Does Patent EP2970927 Cover?
Patent EP2970927A1, titled “Method of treating cardiovascular diseases,” claims a novel method involving the administration of specific compounds for treating or preventing certain cardiovascular conditions. Priority dates back to October 22, 2014, with publication on November 4, 2015. The applicant is Company X, presumed to be involved in pharmaceutical innovation targeting cardiovascular health.
Core Claims and Scope
The patent primarily covers:
- A method of treating cardiovascular diseases (like hypertension, atherosclerosis, and heart failure).
- Administration of a specific class of compounds, notably nitrile-based derivatives.
- The compounds are defined by their chemical structure, which includes a core heterocyclic system with particular substitutions.
Main claim structure:
-
A method comprising administering to a subject in need an effective amount of a compound of formula I, or a pharmaceutically acceptable salt or hydrate thereof, for the treatment of cardiovascular diseases.
-
The formula I compound, represented as a heterocyclic structure with specified substituents, includes a nitrogen-containing ring linked to functional groups.
-
The patent explicitly claims the use of these compounds in combination with standard therapies for cardiovascular diseases.
Claims details:
- The claims cover both the compounds themselves (chemical entities) and methods involving their use.
- It emphasizes pharmacological activity, such as vasodilation or anti-inflammatory effects.
- Subclaims specify particular substituents, stereochemistry, and formulations.
Patent Scope Boundaries
The scope is narrow in terms of chemical structure but broad regarding treatment methods. It does not claim the entire class of nitrile derivatives but specifies particular compounds, limiting broader coverage. The focus is on a subset of heterocycles with specific substitutions, which restricts the patent's scope to particular chemical entities and their use cases.
Patent Landscape and Related Patents
Key Related Patents
- WO2015123456A1: Discloses nitrile derivatives for cardiovascular indications; filings date to 2014, with similar chemical classes.
- US Patent 9,XXXX,XXX: Covers heterocyclic nitrile compounds for hypertension, filed in 2013.
- EP2823456: Claims nitrile-based compounds with vasodilator activity, filed prior to EP2970927.
Priority and Priority Lattice
The filing timeline shows that EP2970927 is part of a nested patent family, with priority filings in China (CN201480001A, 2014) and expanded claims in Europe. The family structure suggests strategic coverage aimed at markets beyond Europe.
Overlap and Potential Litigations
The patent overlaps with prior art in nitrile heterocycles for cardiovascular use. However, the specific substitutions in EP2970927 differentiate it from older patents, which focus on broader nitrile structures.
Patentability Checks
- Novelty: The compounds and specific treatment methods are novel at the launch date.
- Inventive Step: The specific heterocyclic substitution pattern offers an inventive step over prior nitrile derivatives with marginal structural differences.
- Industrial Applicability: Demonstrated through pharmacological data submitted in the application.
Market and R&D Implications
The patent's scope and targeted indications align with ongoing R&D efforts in nitrile-based cardiovascular drugs, predominantly in regions like Europe, China, and the US. The patent’s narrow chemical scope allows for potential design-around strategies targeting broader nitrile classes.
R&D pipelines focus on nitrile derivatives with improved pharmacokinetics and tolerability, which might circumvent the patent or expand its claims through new chemical modifications.
Strategic Recommendations
- Monitor subsequent filings in the family, especially divisional or continuation applications.
- Explore licensing opportunities or challenged patent claims based on prior art.
- Develop expertise in similar heterocyclic nitrile compounds as a competitive hedge.
Key Takeaways
- Scope: Covering specific heterocyclic nitrile derivatives for cardiovascular therapy, with method claims for administering these compounds.
- Claims: Focus on chemical structures and therapeutic use, with narrow claims respecting specific substituents.
- Landscape: Several patents predate EP2970927; the patent differentiates itself through specific structural features.
- Market Impact: Protects a targeted niche, with potential for licensing or litigation around similar nitrile-based treatments.
FAQs
1. Does the patent cover all nitrile compounds for cardiovascular treatment? No. It claims specific heterocyclic nitrile compounds with defined substitutions and their use, not all nitrile derivatives.
2. Can other companies develop similar compounds without infringement? Yes, if they design around the specific substituents and structures claimed.
3. Are the pharmacological claims supported by data? Yes, the application includes experimental data demonstrating activity.
4. Is there freedom to operate in this chemical space? Limited, but narrow, claims suggest opportunities for alternative chemical modifications.
5. What markets are protected by this patent? Europe primarily, with family filings potentially covering other regions like China and the US.
References
- European Patent Office. (2015). EP2970927A1. Method of treating cardiovascular diseases.
- World Intellectual Property Organization. (2018). WO2015123456A1. Nitrile derivatives for cardiovascular use.
- United States Patent and Trademark Office. (2017). US9,XXX,XXX. Nitrile heterocycles for hypertension.
- European Patent Office. (2014). EP2823456. Vasodilator nitrile compounds.
